Company

OCELLBIO Inc. is a biotechnology company incorporated in Seoul in August 2026, dedicated to cell logistics and quality management in advanced regenerative medicine. On the fourth floor of our Gangnam headquarters, we have designed a facility for cell processing, storage and quality control and are preparing for construction.

The core of the business is a central cell logistics and quality hub. Culture, expansion, cryopreservation, quality testing and batch release of clinical-grade cells are carried out by manufacturing facilities licensed under the applicable regulations, while OCELLBIO handles demand consolidation, patient–cell identification, cold storage, cold-chain transport, quality documentation and hospital supply in between.

Our technical foundation is inherited directly from the ARVINBIO research team. Dr. Churl-Ki Min serves as CTO of the research institute and Dr. Haegwon Kim as research advisor, continuing work centered on stem cell induction media and differentiation induction technologies.

OCELLBIO is structured as an independent biotechnology company with capital and operations separated from hospital management support (MSO) companies and clinic networks. This structural separation between clinical revenue and the cell supply business is intended to maintain a clear framework for technology valuation and any future IPO review.